Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK multicentre phase II haploidentical stem cell transplantation with high-dose cyclophosphamide
2011-005889-38Phase 2Unknown
- Sponsor
- University College London
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in acute myeloid leukemia (AML), Hodgkin lymphoma (HL) and hematopoietic malignancies, sponsored by University College London. Primary endpoint: Overall survival at 1 year post transplant. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)Hodgkin lymphoma (HL)hematopoietic malignancies
Beyond the preview
Go deeper on 2011-005889-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005889-38.